Metabolic

Eloralintide

Selective long-acting amylin receptor agonist (LY3841136)

Studied forWeight management2

Investigational; no FDA-approved eloralintide formulation.

What does it do?

Investigational AMY1-selective amylin agonist developed for obesity; human trial evidence is substantially stronger than community-only peptides.

Approved & studied uses

Weight-management research

Selective amylin pathway agonism in adults.

Community uses Reported, unvalidated

Weight and appetite

Source reports 9.5–20.1% mean weight reduction at 48 weeks versus 0.4% placebo; body-composition claims include preclinical findings.

Cardiometabolic markers

Reported waist, glucose, lipid, inflammation and blood-pressure improvements; clinical event prevention unproven.

Reasons people report using it; these do not establish benefit.16

Evidence limits

View research →

Research-market product identity, purity and formulation cannot be established from a publication.2

4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Human safety is unresolved

The checked material does not establish a human adverse-event rate or safe self-use regimen for this exact product.4

Investigational; no FDA-approved eloralintide formulation.

Molecular information

4 16

Amino-acid sequence

Residue count only · sequence not verified4 16

An exact sequence has not been verified for this formulation.

Reference identity · not independently confirmed16

Length37 amino acids

Molecular weight · DaLipidated 37-amino-acid analog (exact MW not publicly disclosed by Lilly)

Formula, sequence notation & identity

Molecular formulaNot independently verified for the exact supplied form4 16

Selective long-acting amylin receptor agonist (LY3841136)

Salt, hydration, glycosylation and blend composition may change the supplied material; no unsupported formula or mass is assigned.

Pep-Pedia identity details

37 amino acids · Lipidated 37-amino-acid analog (exact MW not publicly disclosed by Lilly)

Modified human amylin scaffold with 3 non-coded amino acid residues at positions 11, 15, and 22; C-terminally amidated linear polypeptide (L-configuration only). Full sequence disclosed in US Patent 2022/0288168 A1.

Reference description; checked chemical identity above takes precedence when available.16

Pharmacokinetics

How long does it stay in the body?

Unverified reference estimateNot independently confirmed

Reference half-life12.9 days – 15.3 days15

Route / formulationSource page: Injectable. Exact PK route not verified.

This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.

Elapsed time 12.9 d

50%–55.7%of reference level

Illustrative scenario using an unverified reference estimate. Shading shows the reported half-life range. No midpoint is assumed.

About 3% remaining after 64.5 d–76.5 d

Five half-lives in this estimated model. This is not a prediction of when effects stop.

Evidence and model details

Population: Not established by the reference estimate

Source’s stated attribution: Briere et al. Mol Metab 2025 (PMID 41109426)

Source’s reported peak time: 4.2 days. This has not been independently confirmed and is not used in the elimination curve.

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Phase 2 weight reduction

At 48 weeks, efficacy-estimand changes ranged from approximately −9% to −20% across regimens, compared with −0.4% for placebo. These estimates assume the trial’s analysis conditions.2

Additional phase 1 report

A 2026 publication describes 100 participants in multiple-ascending-dose cohorts. It complements, rather than replaces, the larger phase 2 evidence.3

Reported timelines

Reference & community

Weeks 1–4

Escalation and GI effects.16

Weeks 4–24

Reported appetite/weight and metabolic changes.16

Weeks 24–48

Trial weight loss continued; individual response varies.16

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

Fat loss90%

General wellness3%

Muscle growth3%

Other: Researching only3%

Number of responses to this question: not disclosed.

Source & limitations

The source displays “308 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Interaction categories describe reference claims; investigational combinations require trial-level evidence.

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
SubQSubcutaneous	1 mg — separate escalation cohort	Once weekly	Phase 2 obesity trialHuman study	48 weeks	2
Population 263 adults without type 2 diabetes Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 1, 3, 6 or 9 mg; separate escalation cohorts
SubQSubcutaneous	3 mg — separate escalation cohort	Once weekly	Phase 2 obesity trialHuman study	48 weeks	2
Population 263 adults without type 2 diabetes Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 1, 3, 6 or 9 mg; separate escalation cohorts
SubQSubcutaneous	6 mg — separate escalation cohort	Once weekly	Phase 2 obesity trialHuman study	48 weeks	2
Population 263 adults without type 2 diabetes Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 1, 3, 6 or 9 mg; separate escalation cohorts
SubQSubcutaneous	9 mg — separate escalation cohort	Once weekly	Phase 2 obesity trialHuman study	48 weeks	2
Population 263 adults without type 2 diabetes Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 1, 3, 6 or 9 mg; separate escalation cohorts
SubQ	1 mg weekly	Once weekly	Phase 2 Low Dose (Monotherapy)Reference report	Continuous treatment under investigation; long-term durability data not yet available	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories describe reference claims; investigational combinations require trial-level evidence. Source tabs Injectable
SubQ	3 mg weekly	Once weekly	Phase 2 Mid DoseReference report	Continuous treatment under investigation; long-term durability data not yet available	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories describe reference claims; investigational combinations require trial-level evidence. Source tabs Injectable
SubQ	6 mg weekly	Once weekly	Phase 2 High DoseReference report	Continuous treatment under investigation; long-term durability data not yet available	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories describe reference claims; investigational combinations require trial-level evidence. Source tabs Injectable
SubQ	9 mg weekly	Once weekly	Phase 2 Maximum DoseReference report	Continuous treatment under investigation; long-term durability data not yet available	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories describe reference claims; investigational combinations require trial-level evidence. Source tabs Injectable
SubQ	3 mg → 9 mg over multiple weeks	Once weekly with stepwise escalation	Slow Dose Escalation (improves tolerability)Reference report	Continuous treatment under investigation; long-term durability data not yet available	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories describe reference claims; investigational combinations require trial-level evidence. Source tabs Injectable
SubQSubQ (separate injections)	Eloralintide + tirzepatide (doses under study)	Once weekly each	Combination with Tirzepatide (ATTAIN — Investigational)Reference report	Continuous treatment under investigation; long-term durability data not yet available	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories describe reference claims; investigational combinations require trial-level evidence. Source tabs Injectable

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports16

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: Continuous treatment under investigation; long-term durability data not yet available
Break: Not established; ongoing trials are evaluating long-term continuous dosing

Reported timing

Same day each week, with or without food

Side effects & safety

Human safety is unresolved

The checked material does not establish a human adverse-event rate or safe self-use regimen for this exact product.

Additional reported cautions

Reference reports16

GI effects and fatigue

Dose/escalation-related nausea and fatigue; dehydration risk.

Urgent symptoms

Persistent vomiting/diarrhea, severe abdominal/back pain, allergy, abscess, fainting, tachycardia or hypoglycemia.

Unstudied populations

Pregnancy, lactation, children and many chronic diseases lack established safety.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

10 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Cagrilintide

Avoidance reported

Overlapping amylin action.16

Reference report · Pep-Pedia label: Avoid Combination

Pramlintide

Avoidance reported

Overlapping amylin action.16

Reference report · Pep-Pedia label: Avoid Combination

Semaglutide

Caution reported

No direct evidence cited; additive GI effects.16

Reference report · Pep-Pedia label: Monitor Combination

Retatrutide

Caution reported

Untested; additive GI burden.16

Reference report · Pep-Pedia label: Use Caution

Insulin

Caution reported

Hypoglycemia and meal-absorption concerns.16

Reference report · Pep-Pedia label: Monitor Combination

Oral contraceptives

Caution reported

Possible absorption change; precise timing unestablished.16

Reference report · Pep-Pedia label: Requires Timing

Tirzepatide

Unverified pairing

Combination under investigation.16

Reference report · Pep-Pedia label: Synergistic

Metformin

Unverified pairing

Class extrapolation.16

Reference report · Pep-Pedia label: Compatible

SGLT2 inhibitors

Unverified pairing

Class extrapolation.16

Reference report · Pep-Pedia label: Compatible

Other medicines and research compounds

Not established

No clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.4

Research context

Reconstitution

Product-specific information required

No universal bacteriostatic-water volume or validated preparation method is established for this entry.4

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

Pep-Pedia identifies sponsor-controlled trial presentations and no validated consumer-powder reconstitution protocol.

Clinical-trial handling instructions do not validate independently sourced research powder.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceAMY1R-selective designReported appearanceMethylene thioacetal stabilizationReported appearanceOnce-weekly pharmacokineticsReported appearanceFavorable Phase 2 safety profileReported variationInvestigational status — not commercially availableReported variationLong-term durability unknownReported concernResearch-grade material from gray-market vendors

Available forms

No verified packaging examples included.

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Refrigerated lifetime not established

The checked sources do not establish how long this research preparation remains stable and sterile after mixing.16

Full storage notes from Pep-Pedia

Injectable

Refrigerated 2–8°C

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Research findings

Human trials

Source context

Interaction categories describe reference claims; investigational combinations require trial-level evidence.

Compound identity & other names

An investigational amylin receptor agonist with phase 1 and phase 2 human obesity studies. A weekly research regimen is not an approved product instruction.

Investigational; no FDA-approved eloralintide formulation.

How it may work

Promotes satiety through amylin receptors; delayed gastric emptying may affect oral medicines. Receptor selectivity does not establish superiority to untested comparators.16

Phase 2 weight reduction

At 48 weeks, efficacy-estimand changes ranged from approximately −9% to −20% across regimens, compared with −0.4% for placebo. These estimates assume the trial’s analysis conditions.

Additional phase 1 report

A 2026 publication describes 100 participants in multiple-ascending-dose cohorts. It complements, rather than replaces, the larger phase 2 evidence.

Source checks & newer research

Eloralintide: 48-week randomized phase 2 obesity trial

263 adults without type 2 diabetes were randomized. Mean weight change ranged about −9% to −20% across active regimens versus −0.4% placebo; GI adverse effects varied with dose/escalation. This establishes monotherapy trial efficacy, not research-vial equivalence.

Human randomized phase 2 trial; peer-reviewed Lancet report17

EloraTZP 48-week phase 2b results announced September 30, 2026

Sponsor reported 367 adults with obesity/overweight and type 2 diabetes: highest combination arm lost23.3% versus14.8% with tirzepatide15 mg; A1C fell2.9 versus2.4 percentage points. Adverse-event discontinuations were10.8–27.0% across combination arms versus2.9% with tirzepatide. These are sponsor-announced results, not a checked peer-reviewed publication.

Sponsor announcement of randomized phase 2b results18

Research areas and evidence gaps

Weight-management research. Selective amylin pathway agonism in adults.2

Research-market product identity, purity and formulation cannot be established from a publication.

Community reports Unvalidated

Weight discussions as described by Pep-Pedia.4

No representative survey, independently verified products, or controlled outcomes.

Search coverage and review status

The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.

Checked: 2026-10-12
Search: eloralintide 2026 phase 2 trial site:pubmed.ncbi.nlm.nih.gov
Catalog: Pep-Pedia ↗ · 11 listed references retained

Targeted search, not an exhaustive systematic review.
Bibliography-only entries are retained for traceability and are not treated as verified findings.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

18 sources

1Phase 2 Monotherapy Trial in Obesity — 48-Week Results (2025)Trial · 2025 · thelancet.comAbstract checked

AI-PREPARED SUMMARY

263 participants; efficacy-estimand mean weight change reached approximately −20% in selected 9 mg regimens versus −0.4% with placebo.

Pep-Pedia bibliography · Checked 2026-10-12

Original source

2Eloralintide for obesity: 48-week randomized phase 2 trialTrial · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

263 participants; efficacy-estimand mean weight change reached approximately −20% in selected 9 mg regimens versus −0.4% with placebo.

Phase 2 weight reduction

At 48 weeks, efficacy-estimand changes ranged from approximately −9% to −20% across regimens, compared with −0.4% for placebo. These estimates assume the trial’s analysis conditions.

Additional research · Checked 2026-10-12

Original source

3Eloralintide phase 1 proof of conceptTrial · 2026 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

2026 report of a randomized multiple-ascending-dose program in 100 participants; adds early development evidence, not long-term outcomes.

Additional phase 1 report

A 2026 publication describes 100 participants in multiple-ascending-dose cohorts. It complements, rather than replaces, the larger phase 2 evidence.

Additional research · Checked 2026-10-12

Original source

4Pep-Pedia: Eloralintide — community referenceCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.

Original source

5Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptResearch reference · Accessed 2026 · pmc.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Day-29 weight changes were −2.5% at 4 mg and −4.4% at 12 mg; the reported half-life was 310–366 hours.

Reported population / model
Humans (N=48, healthy adults)

Reported study details
Single SC dose 0.04–12 mg · 29-day observation · −2.5% (4 mg) and −4.4% (12 mg) body weight at day 29

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

6Preclinical Receptor Selectivity & Efficacy in Diet-Induced Obese Rats (2025)Research reference · 2025 · sciencedirect.comPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Obese rats lost up to 12.3% weight; the source attributes 85% to fat and reports less lean loss and taste aversion than cagrilintide.

Reported population / model
DIO rats

Reported study details
0.1–100 nmol/kg every 3 days · Weight loss up to −12.3% at day 13

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

7ATTAIN Phase 2 Combination Trial with TirzepatideTrial registry · Accessed 2026 · clinicaltrials.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: This is a registered comparison of eloralintide alone and with tirzepatide; the card supplies planned endpoints rather than results.

Reported population / model
Humans, T2D + obesity

Reported study details
Eloralintide ± tirzepatide · 48-week primary endpoint

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

8Phase 2 Monotherapy Programs (NCT06297616, NCT06916091)Trial registry · Accessed 2026 · clinicaltrials.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The card lists additional weekly monotherapy programs and development plans; it provides no completed efficacy results for those registrations.

Reported population / model
Humans with obesity

Reported study details
Once-weekly SC · Multi-dose, dose-escalation designs

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

9Receptor Pharmacology — Translational Selectivity (Briere et al. 2025)Research reference · 2025 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Cell assays reported hAMY1R EC50 of 23.9 pM versus 291 pM at CTR and 254 pM at AMY3R; clinical tolerability cannot be inferred directly.

Reported population / model
In vitro human and rat receptor cells

Reported study details
cAMP and ligand binding · EC50 = 23.9 pM (hAMY1R)

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

10Lilly's selective amylin agonist eloralintide: phase 2 sponsor reportSponsor report · Accessed 2026 · lilly.gcs-web.comLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

11Study of LY3841136 in adults with obesity or overweight (NCT06230523)Trial registry · Accessed 2026 · clinicaltrials.govLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

12Single ascending dose study of LY3841136 in healthy participants (NCT05295940)Trial registry · Accessed 2026 · clinicaltrials.govLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

13Long acting amylin receptor agonists and uses thereof — US20220288168A1Patent · Accessed 2026 · patents.google.comLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

14What to know about eloralintideSponsor report · Accessed 2026 · lilly.comLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

15Pep-Pedia: Eloralintide — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Lists a half-life of 12.9 days – 15.3 days and a peak time of 4.2 days. Stated attribution: Briere et al. Mol Metab 2025 (PMID 41109426). This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source

16Pep-Pedia: Eloralintide — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source

17Eloralintide: 48-week randomized phase 2 obesity trialTrial · 2025 · pubmed.ncbi.nlm.nih.govPrimary source checked

AI-PREPARED SUMMARY

Eloralintide: 48-week randomized phase 2 obesity trial

Additional primary-source check · Checked 2026-10-12

Original source

18EloraTZP 48-week phase 2b results announced September 30, 2026Sponsor report · 2026 · investor.lilly.comPrimary source checked

AI-PREPARED SUMMARY

EloraTZP 48-week phase 2b results announced September 30, 2026

Additional primary-source check · Checked 2026-10-12

Original source

What does it do?

Approved & studied uses

Weight-management research

Community uses Reported, unvalidated

Weight and appetite

Cardiometabolic markers

Evidence limits

Key safety information

Human safety is unresolved

Molecular information

Amino-acid sequence

How long does it stay in the body?

What to expect

Study outcomes

Phase 2 weight reduction

Additional phase 1 report

Reported timelines

Weeks 1–4

Weeks 4–24

Weeks 24–48

Experience

Primary goal

Effectiveness

Dosage frequency

How discovered

Side effects

Duration of use

Age range

Gender

Would recommend

Doses & schedules

Cycles & timing

Injectable

Reported timing

Side effects & safety

Human safety is unresolved

Additional reported cautions

GI effects and fatigue

Urgent symptoms

Unstudied populations

Combinations & interactions

Cagrilintide

Pramlintide

Semaglutide

Retatrutide

Insulin

Oral contraceptives

Tirzepatide

Metformin

SGLT2 inhibitors

Other medicines and research compounds

Reconstitution

Injectable

Available forms

Storage after mixing

Reconstituted research vials

Research findings

Source context

Phase 2 weight reduction

Additional phase 1 report

Source checks & newer research

Eloralintide: 48-week randomized phase 2 obesity trial

EloraTZP 48-week phase 2b results announced September 30, 2026

References